Ligand validation:4CQX

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4CQX designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4CQX_NAG_C_1322	80%	53%	0.093	0.94	0.51	1.29	-	2	0	0	100%	0.9333
4CQX_NAG_A_1321	79%	56%	0.117	0.964	0.48	1.21	-	3	0	0	100%	0.9333
4CQX_NAG_E_1323	78%	54%	0.109	0.952	0.55	1.22	-	3	0	0	100%	0.9333
4CQX_NAG_A_1323	63%	36%	0.111	0.904	0.34	2.12	-	3	0	0	100%	0.9333
4CQX_NAG_E_1321	62%	50%	0.133	0.926	0.56	1.35	-	2	0	0	100%	0.9333
4CQX_NAG_A_1322	44%	21%	0.14	0.865	0.87	2.41	1	6	0	1	100%	0.9333
4CQX_NAG_C_1321	39%	43%	0.191	0.898	0.78	1.43	-	3	0	0	100%	0.9333
4CQX_NAG_E_1322	28%	42%	0.228	0.882	0.56	1.67	-	5	0	1	100%	0.9333
4CQX_NAG_E_1324	22%	47%	0.171	0.782	0.46	1.54	-	3	0	0	100%	0.9333
4CQW_NAG_A_1011	80%	55%	0.117	0.966	0.45	1.25	-	1	0	0	100%	0.9333
4CQY_NAG_A_1323	75%	56%	0.101	0.934	0.47	1.19	-	2	0	0	100%	0.9333
4CQV_NAG_C_1011	59%	62%	0.156	0.94	0.49	0.97	-	2	0	0	100%	0.9333
5E2Z_NAG_C_1001	39%	80%	0.176	0.882	0.38	0.47	-	-	0	0	100%	0.9333
5E30_NAG_E_1001	15%	74%	0.272	0.831	0.52	0.5	-	-	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333
5U7O_NAG_B_704	100%	88%	0.024	0.989	0.23	0.44	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.